{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:43:41Z","timestamp":1793133821891,"version":"4.5.0"},"reference-count":61,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2013,10,4]]},"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the efficacy and safety of eculizumab for patients with atypical haemolytic uraemic syndrome (aHUS), compared with current treatment options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A systematic review was performed according to the general principles of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. All study designs were included, except case histories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>All patients diagnosed with aHUS were included; no age restrictions were used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Eculizumab compared with current treatment options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Identification of studies<\/jats:title>\n                    <jats:p>12 databases were searched. Additional searches were performed through the Food and Drug Administration (FDA) and the Electronic Medicines Compendium websites, Google internet searches and contacting clinical experts. Reference lists of relevant articles were checked for additional studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>2 small, uncontrolled prospective multinational, multicentre studies and one small uncontrolled multinational, multicentre retrospective study were included. No meta-analyses were performed. Compared with baseline measures, thrombotic microangiopathy event-free status was achieved in 84% of patients in the prospective studies. Adverse events, as documented by enrolling investigators were frequent, with upper-respiratory tract infection affecting a third of patients. No deaths or episodes of meningitis or meningococcal septicaemia occurred in the prospective studies. Results of the study extension phases up to 114\u2005weeks indicate that the benefits of the treatment are sustained.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Eculizumab is clinically effective for the treatment of aHUS. Further research is needed to evaluate eculizumab, ideally using patient-related clinical outcomes. If randomised studies are not feasible, study investigators should ensure that the threat of bias is minimised in future studies of eculizumab with respect to the reporting of patient recruitment and selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2013-003573","type":"journal-article","created":{"date-parts":[[2013,11,4]],"date-time":"2013-11-04T20:26:43Z","timestamp":1383596803000},"page":"e003573","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":95,"title":["A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)"],"prefix":"10.1136","volume":"3","author":[{"given":"John","family":"Rathbone","sequence":"first","affiliation":[{"name":"School of Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kaltenthaler","sequence":"additional","affiliation":[{"name":"School of Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Richards","sequence":"additional","affiliation":[{"name":"Centre for Complement & Inflammation Research, Imperial College, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Tappenden","sequence":"additional","affiliation":[{"name":"School of Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Bessey","sequence":"additional","affiliation":[{"name":"School of Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cantrell","sequence":"additional","affiliation":[{"name":"School of Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2013,11,4]]},"reference":[{"key":"2025121510313757000_3.11.e003573.1","first-page":"905","article-title":"Hamolytisch-uramische syndrome: bilateral Nierenrindennekrosen bei akuten erworbenen hamolytischen Anamien","volume":"85","author":"Gasser","year":"1955","journal-title":"Schweiz Med Wochenschr"},{"key":"2025121510313757000_3.11.e003573.2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.07.038"},{"key":"2025121510313757000_3.11.e003573.3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/sj.ki.5001581","article-title":"A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders","volume":"70","author":"Besbas","year":"2006","journal-title":"Kidney Int"},{"key":"2025121510313757000_3.11.e003573.4","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-1"},{"key":"2025121510313757000_3.11.e003573.5","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hci128"},{"key":"2025121510313757000_3.11.e003573.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07916.x"},{"key":"2025121510313757000_3.11.e003573.7","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04760512"},{"key":"2025121510313757000_3.11.e003573.8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/MOP.0b013e32835df48a","article-title":"Complement disorders and hemolytic uremic syndrome","volume":"25","author":"Joseph","year":"2013","journal-title":"Curr Opin Pediatr"},{"key":"2025121510313757000_3.11.e003573.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-007-0604-1"},{"key":"2025121510313757000_3.11.e003573.10","first-page":"57","article-title":"cblE-type homocystinuria presenting with features of haemolytic-uremic syndrome in the newborn period","volume":"8","author":"Palanca","year":"2013","journal-title":"JIMD Rep"},{"key":"2025121510313757000_3.11.e003573.11","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2590"},{"key":"2025121510313757000_3.11.e003573.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0902814"},{"key":"2025121510313757000_3.11.e003573.13","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02210310"},{"key":"2025121510313757000_3.11.e003573.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2011.01035.x"},{"key":"2025121510313757000_3.11.e003573.15","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2010.155"},{"key":"2025121510313757000_3.11.e003573.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-008-0964-1"},{"key":"2025121510313757000_3.11.e003573.17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1473-0502(03)00111-3","article-title":"The Canadian apheresis registry","volume":"29","author":"Rock","year":"2003","journal-title":"Transfus Apher Sci"},{"key":"2025121510313757000_3.11.e003573.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-013-2423-x"},{"key":"2025121510313757000_3.11.e003573.19","doi-asserted-by":"crossref","unstructured":"Carter C, Benador N. Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013. Pediatr Nephrol 2013; [Epub ahead of print].","DOI":"10.1007\/s00467-013-2479-7"},{"key":"2025121510313757000_3.11.e003573.20","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1262887"},{"key":"2025121510313757000_3.11.e003573.21","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008080906"},{"key":"2025121510313757000_3.11.e003573.22","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2012.214"},{"key":"2025121510313757000_3.11.e003573.23","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12347"},{"key":"2025121510313757000_3.11.e003573.24","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.07.028"},{"key":"2025121510313757000_3.11.e003573.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2010.02.007"},{"key":"2025121510313757000_3.11.e003573.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2008.12.010"},{"key":"2025121510313757000_3.11.e003573.27","unstructured":"Legendre C, Babu S, Furman R, et al. Safety & efficacy of eculizamab in aHUS patients resistant to plasma therapy: interim analysis from a phase II trial. J Am Soc Nephrol 2011;21:201."},{"key":"2025121510313757000_3.11.e003573.28","unstructured":"Bedrosian C, Babu S, Furman R, et al. Eculizumab is effective in patients resistant to plasma exchange\/infusion with atypical hemolytic uremic syndrome (AHUS): 23rd Congress of the International Society on Thrombosis and Haemostasis: Kyoto, Japan 2011."},{"key":"2025121510313757000_3.11.e003573.29","first-page":"1660","article-title":"Eculizumab in adolescents\/adult patients with atypical hemolytic uremic syndrome resistant to plasma exchange\/infusion: a phase II efficacy and safety study","volume":"26","author":"Loirat","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"2025121510313757000_3.11.e003573.30","doi-asserted-by":"crossref","unstructured":"Greenbaum L Babu S Furman R . Continued improvements in renal function with sustained eculizumab (ECU) in patients (PTS) with typical hemolytic uremic syndrome (aHUS) resistant to plasma exchange\/infusion (PS\/PI). American Society of Nephrology Kidney Week, Philadelphia, 2011.","DOI":"10.1182\/blood.V118.21.193.193"},{"key":"2025121510313757000_3.11.e003573.31","unstructured":"Summaries of Product Characteristics (Soliris): The electronic Medicines Compendium, 2012. http:\/\/www.medicines.org.uk\/emc\/medicine\/19966 ."},{"key":"2025121510313757000_3.11.e003573.32","first-page":"1591","article-title":"A phase II study of eculizumab in adolescent\/adult patients with atypical hemolytic uremic syndrome (aHUS) receiving chronic plasma exchange\/infusion: interim efficacy and safety analysis","volume":"26","author":"Licht","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"2025121510313757000_3.11.e003573.33","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.molimm.2011.06.368","article-title":"Interim analysis of phase II efficacy and safety data for eculizumab in patients with atypical hemolytic uremic syndrome (aHUS) receiving chronic plasma exchange\/infusion","volume":"48","author":"Goodship","year":"2011","journal-title":"Mol Immunol"},{"key":"2025121510313757000_3.11.e003573.34","unstructured":"Soliris (eculizumab) highlights of prescribing information. US Food and Drug Administration; 2007. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125166s172lbl.pdf ."},{"issue":"(s2)","key":"2025121510313757000_3.11.e003573.35","first-page":"499","article-title":"A phase II study of eculizumab in patients with atypical hemolytic uremic syndrome (AHUS) receiving chronic plasma exchange\/infusion: interim analysis","volume":"9","author":"Licht","year":"2011","journal-title":"J Thromb Haemost"},{"key":"2025121510313757000_3.11.e003573.36","unstructured":"Muus P Legendre C Douglas K . Safety & efficacy of eculizumab in aHUS patients on chronic plasma therapy: interim analysis of a phase II trial. American Society of Nephrology (ASN) Annual Meeting on Friday, November 19; 2010."},{"key":"2025121510313757000_3.11.e003573.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208981"},{"key":"2025121510313757000_3.11.e003573.38","first-page":"1663","article-title":"Eculizumab therapy for atypical hemolytic uremic syndrome (aHUS) in pediatric patients: efficacy and safety outcomes from a retrospective study","volume":"26","author":"Simonetti","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"2025121510313757000_3.11.e003573.39","unstructured":"Gruppo R Rodig N Vilalta R . Eculizumab (ECU) therapy for atypical hemolytic uremic syndrome (AHUS) in pediatric patients: efficacy and safety outcomes from a retrospective study. 23rd Congress of the International Society on Thrombosis and Haemostasis 57th Annual SSC Meeting Kyoto Japan, 2011."},{"key":"2025121510313757000_3.11.e003573.40","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010121293"},{"key":"2025121510313757000_3.11.e003573.41","doi-asserted-by":"crossref","unstructured":"Licht C Muus P Legendre C . Eculizumab (ECU) safety and efficacy in atypical hemolytic uremic syndrome (aHUS) patients with long disease duration and chronic kidney disease (CKD): 2-year results 54th ASH annual meeting and exposition. Atlanta, Georgia, USA: World Congress Center, 2012.","DOI":"10.1182\/blood.V120.21.985.985"},{"key":"2025121510313757000_3.11.e003573.42","doi-asserted-by":"crossref","unstructured":"Greenbaum L Legendre C Babu S . Eculizumab (ECU) in atypical hemolytic uremic syndrome (aHUS) patients with progressing thrombotic microangiopathy (TMA): 2-year data 54th ASH annual meeting and exposition. Atlanta, Georgia, USA: World Congress Center, 2012.","DOI":"10.1182\/blood.V120.21.2084.2084"},{"key":"2025121510313757000_3.11.e003573.43","first-page":"509a","article-title":"Eculizumab, a C5 complement-blocking antibody, controls hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) with responses maintained over a prolonged period of therapy","volume":"102","author":"Hillmen","year":"2003","journal-title":"Blood"},{"key":"2025121510313757000_3.11.e003573.44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-1-4614-4118-2_10","article-title":"Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies","volume":"735","author":"Risitano","year":"2013","journal-title":"Adv Exp Med Biol"},{"key":"2025121510313757000_3.11.e003573.45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-244285"},{"key":"2025121510313757000_3.11.e003573.46","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1681\/ASN.2011121186","article-title":"Pathology after eculizumab in dense deposit disease and C3 GN","volume":"23","author":"Herlitz","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2025121510313757000_3.11.e003573.47","unstructured":"Guidelines on clinical trials in small populations. London: European Medicines Agency, 2006. http:\/\/www.ema.europa.eu\/docs\/en_GB\/...guideline\/...\/WC500003615.pdf ."},{"key":"2025121510313757000_3.11.e003573.48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-007252"},{"key":"2025121510313757000_3.11.e003573.49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0809959"},{"key":"2025121510313757000_3.11.e003573.50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0808527"},{"key":"2025121510313757000_3.11.e003573.51","first-page":"27","article-title":"An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document","volume":"33","author":"Campistol","year":"2013","journal-title":"Nefrologia"},{"key":"2025121510313757000_3.11.e003573.52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1100859"},{"key":"2025121510313757000_3.11.e003573.53","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs398"},{"key":"2025121510313757000_3.11.e003573.54","doi-asserted-by":"crossref","first-page":"96","DOI":"10.5482\/HAMO-12-12-0025","article-title":"Complement activation in thrombotic microangiopathy","volume":"33","author":"Karpman","year":"2013","journal-title":"Hamostaseologie"},{"key":"2025121510313757000_3.11.e003573.55","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"key":"2025121510313757000_3.11.e003573.56","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462309090023"},{"key":"2025121510313757000_3.11.e003573.57","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00048-09"},{"key":"2025121510313757000_3.11.e003573.58","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12032"},{"key":"2025121510313757000_3.11.e003573.59","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1399-3046.2011.01585.x","article-title":"Immunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy","volume":"16","author":"Zlamy","year":"2012","journal-title":"Pediatr Transplant"},{"key":"2025121510313757000_3.11.e003573.60","doi-asserted-by":"publisher","DOI":"10.1136\/pmj.78.923.538"},{"key":"2025121510313757000_3.11.e003573.61","unstructured":"Advisory Group for National Specialised Services. Statement from AGNSS regarding eculizumab and tafamidis, 2013. http:\/\/www.specialisedservices.nhs.uk\/news\/view\/132"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2013-003573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:31:47Z","timestamp":1765823507000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2013-003573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":61,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2013,11,4]]},"published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1136\/bmjopen-2013-003573"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2013-003573","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}